Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza

Cidara Therapeutics, Inc. announced that the FDA has accepted the company’s Investigational New Drug application for its lead flu drug-Fc conjugate, CD388 – a highly potent, long-acting antiviral immunotherapy designed to deliver universal prevention and treatment of seasonal and pandemic influenza.